Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (182)
  2. Journal Article (122)
  3. Review (19)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (338)
  2. Center for Hematologic Malignancies (338)
  3. Department of Medicine (338)
  4. Hematologic Malignancies, Division of (338)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (139)
  2. Journal of Clinical Oncology (17)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (155)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (338)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: A randomized phase 3 trial
    Journal Article

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Assessing AML-based risk criteria in patients with accelerated/blastphase MPN treated with less-intensive therapy
    Research Letter

    Shaw, R.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Siddon, A. J.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
    Research Letter

    Akiyama, H.; Nishida, Y.; Chang, K. H.; Bedoy, A. D.; Muftuoglu, M.; Ma, W.; Basyal, M.; Hirschi, Z.; Honma, D.; Tsutsumi, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia
    Review

    Patel, A. A.; Rampal, R. K.
    Haematologica (2025)

    Fulltext@MSK | Save
  • Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
    Research Letter

    Goyal, G.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Lacouture, M. E.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; Diamond, E. L.
    Blood (2025)

    Fulltext@MSK | Save
  • Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
    Journal Article

    Mascarenhas, J.; Maher, K.; Rampal, R.; Bose, P.; Podoltsev, N.; Hong, J.; Chai, Y.; Kye, S.; Method, M.; Harrison, C.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML
    Journal Article

    Fiskus, W.; Mill, C. P.; Bose, P.; Masarova, L.; Pemmaraju, N.; Dunbar, A.; Birdwell, C. E.; Davis, J. A.; Das, K.; Hou, H.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival
    Journal Article

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety
    Review

    Masarova, L.; Mascarenhas, J.; Rampal, R.; Hu, W.; Livingston, R. A.; Pemmaraju, N.
    Cancer (2025)

    Fulltext@MSK | Save
  • Impact of recent translational and therapeutic developments on clinical course of BCR::ABL1-positive and -negative myeloproliferative neoplasms
    Review

    Mughal, T. I.; Mascarenhas, J.; Rampal, R. K.; Bose, P.; Lion, T.; Ajufo, H.; Yacoub, A.; Meshinchi, S.; Masarova, L.; Mesa, R.; more...
    Hematological Oncology (2025)

    Fulltext@MSK | Save